New hope for hard-to-treat pancreatic cancer: targeted drug enters final testing phase
NCT ID NCT07262567
First seen Jan 10, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This study tests a new drug, GFH375, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants must have already tried at least one standard treatment. The goal is to see if GFH375 works better than standard chemotherapy at controlling the cancer and helping people live longer. About 320 adults aged 18-80 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.